Bal Pharma Limited launched the formulation of Favipiravir in the Indian market under the brand name BALflu.
“Favipiravir is an emerging antiviral drug used in patients with mild to moderate Covid. This formulation is available in tablet form with a concentration of 400 mg. Favipiravir inhibits and terminates viral protein synthesis and induces lethal influenza virus metagenesis, ”the company said in a regulatory filing on the stock exchanges.
BALflu (Favipiravir) is a broad spectrum formulation also used in the treatment of 53 types of influenza viruses, including seasonal strains such as Ebola virus, Arenavirus, Bunyavirus, Flovirus, West Nile virus, foot-and-mouth disease virus and Lassa virus.
“BALflu (Favipiravir) is approved by the Comptroller General of Medicines of India (DCGI) for emergency use for the treatment of Covid-19, with a recommended dosage of 1800 mg on the first day, followed by 800 mg of day 2 through 14, ”the company’s release said.
Shailesh Siroya, MD, speaking at the product launch, said BALflu has the effectiveness of clearing the virus faster by 28.7% and is being marketed at an affordable price of ₹ 85 per pill to enable patients in need to access this drug on time. The drug is available in all major markets in India as a prescription drug.